Thrombotic thrombocytopenic purpura (TTP) is a rare life-threatening illness characterized by hemolytic anemia, thrombocytopenia, neurological symptoms and occasionally renal dysfunction. 1, 2 The clinical syndrome results from the widespread deposition of the von Willebrand factor (VWF) and platelet-rich thrombi in the small vessels of multiple organs, which is the pathological hallmark of the disease. TTP may manifest once in a lifetime or may relapse after complete recovery of the initial episode. In recurrent cases, neurological sequelae or death are common final outcomes. 1 Endothelial dysfunction is the central event in the microangiopathic process, and causes the release of ultra large VWF multimers that do not normally circulate in human blood. In healthy subjects, the VWF-cleaving protease, ADAMTS13 (a disintegrin-like and metalloprotease with thrombospondin type I repeats), reduces the ultra large multimers into smaller forms soon after their secretion. Cleavage of VWF multimers by ADAMTS13 occurs at the Tyr842-Met843 peptide bond in the central A2 domain of the VWF subunit. 3 Patients with TTP suffer from severe deficiency of ADAMTS13 that may be constitutive, because of homozygous or double heterozygous mutations in the corresponding gene, 4, 5 or acquired, because of the presence of circulating autoantibodies. 6, 7 In patients with the congenital form of the disease, missense mutations cluster by more than 75% in the first half of Adamts13 gene. Expression studies of the mutated forms showed reduced or absent protein into the cell culture media, suggesting that impaired secretion into the circulation may be the dominant mechanism of ADAMTS13 dysfunction. 5 Patients with congenital TTP have absent or severely depressed ADAMTS13 antigen levels and activity, which limit the cleavage of ultra large VWF multimers, allowing platelet deposition into growing, potentially occlusive thrombi. Plasma infusion is the treatment of choice for patients with congenital ADAMTS13 deficiency. Pre-emptive fresh frozen plasma infusion therapy in a patient with chronic relapsing congenital TTP prevented hemolysis and neurological signs of disease activity and preserved renal function. 8 Plasma therapy was also associated with increase in platelet count until day 7 after the infusion when plasma protease activity had fallen below 5%, indicating that the levels of plasma ADAMTS13 that are needed to prevent the formation of platelet thrombi in the microcirculation and to protect patients from disease manifestations are indeed rather low. Around 25% of patients with chronic relapsing form of TTP (unpublished data from the International Registry of HUS/TTP) actually become plasma dependent and require infusion of large amount of plasma every few weeks to prevent relapses. 9 Moreover, despite the dramatic improvements upon the adoption of plasma infusion in early seventies, 10 the mortality associated with TTP is still high and approaches 10-20%. Plasma manipulation exposes patients to the risk of infections, allergies and fluid volume overload, making the search of alternative treatments a matter of investigation. In this context, replacement therapy using recombinant ADAMTS13 protein could be an option. However, this approach is not feasible at present for several reasons. 11 First of all, recombinant protein is not available at the moment for human use. In addition, the purified protein that has been used in mice seems to be rather unstable 12 and has a very short halflife. 8 In the current study, we sought to examine whether adenoviral vector-mediated gene delivery of ADAMTS13 cDNA was capable to achieve therapeutic plasma levels of functionally active ADAMTS13 protease in Adamts13 knockout mice. Recombinant adenoviral vectors administered systemically infect the liver-the constitutive site of ADAMTS13 production-with high efficiency by virtue of the high hepatic expression of the CAR (coxsackie and adenovirus receptor) receptor. 13, 14 Adenovirus encoding the human form of ADAMTS13 (Ad-ADAMTS13) was constructed by Cre/loxP site-specific recombination ( Figure 1a ) and its ability to infect human fibrosarcoma HT1080 cells was evaluated. Cells were efficiently transfected as documented by ADAMTS13 mRNA expression (Figure 1b) , resulting in the production of the corresponding protein, detected by western blot analysis, in the cell supernatant (Figure 1c) . ADAMTS13 activity was then analyzed by the residual collagen-binding assay (CBA) based on decreased binding affinity of ADAMTS13-cleaved VWF to a collagencoated surface. 15, 16 Assessment of VWF-cleaving protease activity in the supernatant of Ad-ADAMTS13-infected cells showed values ranging from 9.2 to 12.5% (n ¼ 5) in comparison with the activity of normal human plasma pool, arbitrarily defined as 100% (Figure 1d) .
The availability of a mouse strain lacking ADAMTS13 17 was then instrumental to show the feasibility to replace the lacking protease by a gene therapy approach. Complete ADAMTS13 deficiency in mice is not lethal, and it is well tolerated without signs of histopathological lesions in the organ tissues. 17 Knockout The activity of the secreted human ADAMTS13 protein was measured by the residual collagen-binding assay (CBA) using CPD fresh frozen plasma as source of von Willebrand factor (VWF), as previously described. 15 Briefly, serial dilution of the supernatant samples and of the normal human plasma pool (NHP) in buffer containing urea were incubated with BaCl 2 to achieve degradation of endogenous VWF. Human collagen type III (3 mg ml À1 , Walter Occhiena, Milano, Italy) was used for the CBA. The values of ADAMTS13 activity were read from a dose-response curve obtained with citrated NHP from at least 25 healthy donors and expressed as percentage of activity ( ± s.e.) with respect to that of NHP considered as 100%.
ADAMTS13 gene therapy in knockout mice
P Trionfini et al mice were administered 0.5 Â 10 9 or 1 Â 10 9 p.f.u. of Ad-ADAMTS13 through the lateral tail vein. As control group, Adamts13 À/À mice received 1 Â 10 9 p.f.u. of an adenovirus encoding for the reporter gene, Ad-bGal. At 1 week after the injection, animals were killed and transgene expression was evaluated in different organs by reverse transcriptase PCR. Although the transfection with the low dose was restricted to the liver, expression of the transgene was found in the liver, kidney, lung, heart and spleen with the high dose of Ad-ADAMTS13 (Figure 2a) . To localize the transgene product, X-gal histochemistry was performed on frozen specimens obtained from Ad-bGal-treated mice. At 1 week after injection, liver was extensively transduced, resulting in the production of large amount of the recombinant Liver sections from knockout mice injected with the Ad-ADAMTS13 and killed after 1 week were stained with hematoxylin and eosin, and examined for hepatic pathology. Sites of focal mixed inflammatory infiltrate were observed, mainly localized in the perivascular/ ), generated by Motto, 17 were housed in conventional animal facilities, and maintained and manipulated in conformity with the institutional guidelines and in compliance with national and international laws and policies. Mice (n ¼ 6 for each groups, if not otherwise specified) received a single injection of 0.5 Â 10 9 or 1 Â 10 9 p.f.u. of Ad-ADAMTS13 or Ad-bGal through the lateral tail vein. Mice were killed 1 week after injection by CO 2 inhalation. Specimens from liver, kidney, lung, heart, brain and spleen were collected, and the RNA was extracted using Trizol. (a) ADAMTS13 mRNA tissue localization evaluated by reverse transcriptase PCR 1 week after adenoviral injection. Liver mRNA sample from Ad-bGal-treated mice was used as negative control. (b-g) Tissue localization of b-galactosidase was analyzed by X-gal staining. Threemicrometer cryosections of frozen tissues were fixed in acetone at room temperature for 10 min, washed twice with phosphate-buffered saline and incubated at 37 1C overnight with X-gal solution (Stratagene). Sections were then counterstained using hematoxylin and eosin and mounted for microscopic evaluation. Representative pictures of liver (b), kidney (c), lung (d), heart (e), brain (f) and spleen (g) from mice injected with 1 Â 10 9 p.f.u. of Ad-bGal and killed 1 week later (original magnification, Â 40). No staining was observed in tissues from knockout control mice.
ADAMTS13 gene therapy in knockout mice P Trionfini et al pericentral areas and around the portal areas (Supplementary Figure 1 ). To determine the extent of hepatotoxicity in response to adenoviral injection, plasma levels of liver-derived transaminases, the alanine aminotransferase and the aspartate aminotransferase, were also examined in control and injected mice killed after 1, 4, 8 and 12 weeks. Although aspartate aminotransferase levels did not change at any experimental time points compared with untreated knockout mice, alanine aminotransferase showed a significant sevenfold increase 4 weeks after treatment, but the value was normalized already at 8 weeks (Po0.05 assessed by ANOVA (analysis of variance) using Bonferroni's correction).
To verify whether ADAMTS13 gene transfer effectively translated into the production and secretion of the protease, ADAMTS13 antigen levels were measured in plasma of mice by ELISA (enzyme-linked immunosorbent assay). As shown in Figure 3a , very high levels of ADAMTS13 (3.8 ± 2.4 mg ml À1 ) were detected in the plasma of Ad-ADAMTS13-treated mice with respect to Ad-bGal controls that showed undetectable values. We then tested the activity of ADAMTS13 by the residual CBA after incubation of plasma from Ad-ADAMTS13 or Ad-bGal-treated mice with human multimeric VWF as a substrate. Plasma from mice receiving Ad-ADAMTS13 showed a remarkable increase in the protease activity, which accounted for 293±68% with respect to the 100% activity of normal human plasma (Figure 3b) . No detectable activity was found in plasma from Ad-bGal controls. ADAMTS13 activity was further confirmed by evaluating the capacity of plasma from treated mice to cleave recombinant human VWF A 1 A 2 A 3 domains that contain the cleavage site. The amount of the proteolytic fragment (samples from Ad-ADAMTS13-treated mice were diluted 1:5), visualized by western blot using a mouse monoclonal antibody against the A3 domain, was quantified by densitometric analysis. Consistent with the data obtained from CBA, plasma of Ad-ADAMTS13-treated animals showed 271±26% of activity with respect to that of normal human plasma. Addition of EDTA, a specific inhibitor of the metalloprotease ADAMTS13, completely prevented the recombinant human VWF A 1 A 2 A 3 cleavage, suggesting that proteolysis was ADAMTS13 specific (Figure 3c ). No activity was detected in plasma from Ad-bGal-treated mice, both in the absence or presence of EDTA. We subsequently Reactions were analyzed by sodium dodecyl sulfate polyacrylamide gel electrophoresis on a 10% acrylamide gel and western blotting using a mouse monoclonal antibody directed against an epitope located within the A 3 domain. Under these conditions, the carboxyl terminal fragment of 30 kDa derived from cleavage of rhVWF A 1 A 2 A 3 domains was visualized. Densitometric analysis was performed using Scion Image 1.62c. A representative western blot is shown.
P Trionfini et al investigated whether ADAMTS13 released in the blood after gene therapy was biologically functional in limiting thrombus formation. Whole blood from ad hoc Ad-ADAMTS13 and Ad-bGal-treated mice was used to test the formation of platelet thrombi on immobilized collagen. Blood was perfused over a collagen-coated surface in a plate flow chamber and thrombus formation under flow was assessed by computational analysis (Figure 4a ). Thrombus formation was evaluated in parallel using whole blood from B/129 mice that possess normal ADAMTS13 activity and their value was considered as baseline. Lower platelet deposition on collagen-coated surface, which resulted in a significantly reduced area covered by thrombi (49±18.5%, Po0.05), was found using whole blood from mice expressing ADAMTS13 with respect to Ad-bGal controls (considered as 100%, Figure 4b) . To evaluate the time-course of the recombinant protein production, Ad-ADAMTS13 or Ad-bGal-treated mice were killed at 4, 8 and 12 weeks after injection and the protein activity was measured by CBA. As shown in Figure 5a , protein activity was still detected in the circulation of Ad-ADAMTS13-treated mice at each time points (16.7±2.9%, 11.6±0.6% and 13.2±0.7% at 4, 8 and 12 weeks, respectively), although at lower levels than those measured 1 week after injection. It is known that adenoviral vectors induce strong innate and adaptive immune responses that might account for the drop in protease activity. To evaluate such hypothesis, we investigated the formation of anti-adenoviral antibodies by ELISA. As shown in Figure 5b , mice administered with adenovirus started to develop anti-adenoviral antibodies 1 week after injection, reaching statistically significant levels at 4, 8 and 12 weeks. Inhibitory antibodies against the transgene were also detected at 4, 8 and 12 weeks after treatment by incubating a mixture of normal human plasma with plasma from treated mice for 30 min at 37 1C and then measuring the ADAMTS13 activity by CBA. 15 Despite the presence of antibodies, whole blood from Ad-ADAMTS13-treated mice killed at 12 weeks still showed a lower platelet deposition to collagen-coated surface with respect to Ad-bGal controls, resulting in a 10.2 ± 2.9% reduction of the area covered by thrombi.
These data show that intravenous administration of Ad-ADAMTS13 induces the release of a functionally active protease into the circulation for at least 12 weeks at levels consistently above 5-10%, which is sufficient to protect patients from disease recurrences. 8 Recent studies have shown successful correction of the prothrombotic phenotypes in Adamts13 À/À mice by a single in utero injection of lentiviral vector encoding human Adamts13 gene, 19 or by autologous transplantation of hematopoietic progenitor cells transduced ex vivo using a lentiviral vector encoding murine Adamts13. 20 The use of À/À , and from B/129 mice were analyzed for their ability to form platelet thrombi on immobilized collagen (n ¼ 9 for each group). (a) Whole blood, collected into heparin (10 U ml À1 f.c.), was perfused for 2 min over collagen (derived from equine tendon, 200 mg ml À1 ; Mascia Brunelli, Milan, Italy)-coated slides at shear stress of 60 dynes cm À2 . 18 Platelet thrombi adherent to the collagen were fixed and stained with May Grunwald-Giemsa stain. Representative images are shown. (b) The percentage of the surface occupied by thrombi was evaluated by computational analysis with Scion Image 1.62c. The difference between the area covered by thrombi from Adamts13 À/À and B/129 mice (with normal ADAMTS13 activity) was set as 100%. Results are expressed as percentage of the area covered by thrombi from Ad-ADAMTS13-treated mice (mean±s.e.) with respect to 100% after subtraction of that from B/129 mice. Statistical analysis was assessed by analysis of variance (ANOVA) using the Fisher correction stating the corresponding *Po0.05 as statistically significant. ADAMTS13 gene therapy in knockout mice P Trionfini et al lentivirus, however, bears a number of hurdles that should be overcome before clinical application. These include the choice of the optimal gestational age for vector delivery to reduce mortality associated with the procedure and the potential of insertional mutagenesis and germ-line alteration associated with lentiviral vectorbased approach. The vector used in the present study also bears some limitations. The main disadvantage of adenovirus resides in its inherent immunogenicity that, however, could be circumvented by genetic or chemical modifications of the adenoviral genome and/or capsid. 21, 22 PEGylated adenovirus can indeed protect the vectors from pre-existing and adaptive immune responses, allowing new protein production after a second administration. 23 An alternative approach is the use of non-pathogenic adeno-associated virus whose main limitation is the reduced cargo capacity (4.3 kb). However, generation of hybrid serotypes with extended packaging capacity (up to 8.9 kb) has been recently described, thus expanding the therapeutic potential of this vector system for diseases due to mutations in large genes. 24 Collectively, these findings represent the proof of principle that gene therapy can restore ADAMTS13 plasma levels and activity in knockout mice. More studies are mandatory to better identify the ideal gene delivery system. Once the most suitable one is established, novel therapeutic perspectives could open for patients affected by the congenital form of TTP. A 96-well ELISA plate was coated with 100 ml of purified adenovirus (1 Â 10 8 p.f.u. per well) kept overnight at 4 1C in phosphate-buffered saline (PBS) buffer and blocked in PBS containing 1% skimmed milk powder for 1 h at room temperature. Plasma samples diluted 1:1000 were then added to the antigen-coated wells and incubated for 3 h at 37 1C. Finally, wells were incubated with anti-mouse IgG-horseradish peroxidase conjugate. The chart represents the optical densities of samples (490 nm) as a measure of the relative concentration of antiadenovirus antibody . Data are expressed as mean ± s.e. Statistical analysis was assessed by ANOVA using the Bonferroni's correction. *Po0.05 versus untreated mice and mice given adenovirus and killed at 1 week.
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